Intellia Therapeutics, a preclinical biotech developing gene editing therapies using CRISPR/Cas9 technology, raised $108 million by offering 6 million shares at $18, the high end of the range of $16 to $18. Intellia Therapeutics plans to list on the Nasdaq under the symbol NTLA. Credit Suisse, Jefferies and Leerink Partners acted as lead managers on the deal.
